Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gramicidin is a naturally occurring mixture of linear peptide antibiotics (primarily gramicidin A, B, and C, collectively known as gramicidin D) derived from the soil bacterium Brevibacillus brevis. It functions as an ionophore, forming channels within bacterial cell membranes. This action disrupts the cell's vital ion gradients, particularly by allowing the passive diffusion of monovalent cations like sodium and potassium, leading to membrane depolarization and ultimately bacterial cell death. Due to its significant toxicity upon systemic administration, gramicidin is exclusively used topically to treat superficial bacterial infections of the eye, ear, and skin, and is often formulated in combination with other antibiotics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gramicidin.